Medicare GLP-1 Coverage 2026: Wegovy & Zepbound Rules

Back to Blog

The regulatory and coverage landscape for glucagon-like peptide-1 (GLP-1) receptor agonists under Medicare has undergone significant modification. While the Social Security Act historically excluded agents used for weight management from Part D coverage, emerging clinical trial data has prompted critical policy exceptions. This clinical-policy review analyzes the 2026 Medicare GLP-1 coverage guidelines, detailing the cardiovascular risk reduction exception established by the SELECT trial, the operational parameters of the July 1, 2026 Medicare Bridge Program, and affordable out-of-pocket alternatives for beneficiaries who do not meet narrow coverage criteria.

Does Medicare Cover GLP-1 Medications for Weight Loss?

The short answer is no, Medicare does not cover Wegovy, Zepbound, or other GLP-1 medications if they are prescribed strictly for weight loss. This exclusion is not a policy choice made by individual Medicare plans; it is a federal statutory requirement. When Congress created the Medicare Part D prescription drug benefit in the Medicare Modernization Act of 2003, it explicitly excluded certain categories of drugs from coverage. Among those excluded categories were drugs used for anorexia, weight loss, or weight gain.

At the time the law was drafted, weight loss drugs were largely viewed by policymakers as lifestyle medications with limited clinical value and significant safety risks. The metabolic science of obesity has progressed substantially since 2003, with obesity now recognized as a chronic disease by major medical organizations. However, until Congress acts to amend the Social Security Act, the statutory prohibition on covering drugs solely for weight management remains in effect. Consequently, if a physician submits a prescription for Wegovy or Zepbound with a primary diagnosis code of obesity (ICD-10 code E66.9) and no other comorbidities, the Medicare Part D plan is legally obligated to deny coverage.

What Is the Medicare Cardiovascular Exception for Wegovy?

While the weight loss exclusion remains, a major policy shift occurred in early 2024, continuing into 2026. The Centers for Medicare & Medicaid Services (CMS) issued updated guidance permitting Part D plans to cover anti-obesity medications that receive FDA approval for an additional, medically accepted indication. This policy shift was directly triggered by the FDA approval of Wegovy (semaglutide 2.4 mg) to reduce the risk of major adverse cardiovascular events—including cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke—in adults with established cardiovascular disease and obesity or overweight.

This approval was based on the landmark SELECT trial, a randomized clinical trial published in the New England Journal of Medicine. Under the CMS guidelines, a Medicare Part D plan can cover Wegovy if the patient meets the specific criteria approved by the FDA:

• The patient must have established cardiovascular disease (such as a documented history of coronary artery disease, myocardial infarction, stroke, or peripheral arterial disease).
• The patient must have a body mass index (BMI) of 27 kg/m² or greater.
• The medication must be prescribed for the specific purpose of cardiovascular risk reduction.

If these criteria are met, the Part D plan can include Wegovy on its formulary. However, patients must still undergo prior authorization, and plans are not required to cover Zepbound (tirzepatide) under this exception unless it receives a similar cardiovascular risk reduction indication from the FDA.

How Does the July 1, 2026 Medicare GLP-1 Bridge Program Work?

To help seniors who are transitioning from commercial employer plans onto Medicare, CMS has introduced the Medicare GLP-1 Bridge Program. Historically, patients transitioning onto Medicare faced immediate coverage disruption because commercial plans often covered anti-obesity medications while Medicare Part D plans did not. This disruption led to patients abruptly stopping their therapy, which often resulted in rapid weight regain and metabolic rebound.

The GLP-1 Bridge Program provides a transitional care window. Under this policy, when an individual first enrolls in Medicare Part D, the plan must offer a temporary transitional supply of their current GLP-1 medication (up to a 90-day supply) while the physician submits the necessary prior authorization documentation. This transition period is designed to prevent clinical gaps in care. It gives the healthcare provider time to document the patient's cardiovascular history, check BMI criteria, and submit appeals if the initial coverage request is denied.

What Are the Prior Authorization Criteria for Seniors?

For seniors who meet the cardiovascular exception, obtaining actual coverage still requires passing a prior authorization (PA) review. Part D insurance administrators use PA criteria to ensure the medication is being used for covered indications rather than off-label weight loss. The prior authorization process typically requires the prescribing physician to submit the patient's medical records detailing:

1. Documented Cardiovascular Disease: The medical record must contain objective evidence of cardiovascular disease. This can include hospital discharge summaries for myocardial infarction or stroke, angiogram reports showing significant coronary artery stenosis, or documentation of revascularization procedures (such as coronary artery bypass grafting or angioplasty).
2. BMI Tracking: The physician must submit recent height and weight measurements documenting a BMI of 27 kg/m² or higher.
3. Lifestyle Program Participation: Many plans require documentation that the patient is participating in, or has tried, a structured lifestyle modification program (including diet and exercise) alongside the pharmacotherapy.

Even if the PA is approved, Medicare beneficiaries face significant financial barriers. Unlike commercial plans, where manufacturer savings cards can bring copays down to $25 per month, Medicare patients are legally prohibited from using these cards due to the federal Anti-Kickback Statute. Consequently, seniors must pay the plan's standard formulary copay, which can range from $150 to over $400 per month depending on their coverage phase (deductible, initial coverage, or coverage gap).

What Are the Out-of-Pocket Alternatives for Medicare Patients?

Because the clinical criteria for the cardiovascular exception are narrow, the vast majority of seniors who struggle with obesity do not qualify for Medicare coverage. For these self-paying patients, purchasing brand-name Wegovy or Zepbound at retail prices is financially impossible. Without insurance, Wegovy carries a retail list price of approximately $1,349 per month, and Zepbound costs about $1,059 per month.

This cost barrier has led many seniors to seek out-of-pocket alternatives, primarily compounded semaglutide. Compounding is the process of combining, mixing, or altering ingredients to create a customized medication for an individual patient. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies are permitted to prepare compounded versions of medications if they receive a patient-specific prescription.

Through telemedicine platforms like Losing Weight RX, compounded semaglutide is available at a flat rate of $146 per month. This pricing model provides an accessible path for seniors who do not meet Medicare's narrow cardiovascular criteria. The compounded medication is prepared by state-licensed compounding pharmacies that utilize high-purity active pharmaceutical ingredients (API) sourced from FDA-registered facilities. By bypassing the insurance system entirely, seniors can access consistent metabolic care without the high cost of retail brand-name drugs.

---

---